Prenatal Diagnosis of BACs-on-Beads Assay in 3647 Cases of Amniotic Fluid Cells
Tóm tắt
To evaluate the diagnostic accuracy of the BACs-on-Beads (BoBs) assay for the rapid diagnosis of common aneuploidies and microdeletion syndromes. BACs-on-Beads and chromosomal karyotyping were used for detecting 3647 cases of amniotic fluid samples with indications for prenatal diagnosis, which were collected from January 2015 to June 2017 in Xijing Hospital. Fluorescence in situ hybridization (FISH) or chromosomal microarray analysis (CMA) provided further validation. The overall abnormality detection rate (BoBs combined with karyotyping) was 7.73% (282/3647). A total of 209 chromosomal aneuploidies, 10 mosaic cases, 11 microdeletion/microduplication syndromes, and 52 structural abnormalities were observed. Both assays were concordant for trisomy 21 (4.22%, 154/3647), trisomy 18 (0.69%, 25/3647), trisomy 13 (0.05%, 2/3647), and sex chromosome aneuploidies (0.77%, 28/3647). Meanwhile, DiGeorge syndrome (0.05%, 2/3647), 22q11.2 microduplication (0.08%, 3/3647), Smith-Magenis syndrome (0.03%, 1/3647), 17p11.2 microduplication (0.03%, 1/3647), Wolf-Hirschhorn syndrome (0.03%, 1/3647), Williams-Beuren syndrome (0.03%, 1/3647), Cri du Chat syndrome (0.03%, 1/3647), and Miller-Dieker syndrome (0.03%, 1/3647) were identified by BoBs assay, thus giving the incidence of the detection of these syndromes of 0.30% (11/3647). BACs-on-Beads assay is a reliable test for rapid detection of common aneuploidies and microdeletion syndromes, combining with karyotyping, FISH, and CMA, to improve the efficiency and accuracy of prenatal diagnosis to alleviate maternal emotional anxiety.
Tài liệu tham khảo
Rosano A, Botto LD, Botting B, Mastroiacovo P. Infant mortality and congenital anomalies from 1950 to 1994: an international perspective. J Epidemiol Community Health. 2000;54(9):660–666.
Caramins MC, Saville T, Shakeshaft R, et al. A comparison of molecular and cytogenetic techniques for the diagnosis of pregnancy loss. Genet Med. 2011;13(1):46–51.
Gross SJ, Bajaj K, Garry D, et al. Rapid and novel prenatal molecular assay for detecting aneuploidies and microdeletion syndromes. Prenat Diagn. 2011;31(3):259–266.
Choy RK, Chen Y, Sun XF, Kwok YK, Leung TY. BACs-on-beads: a new robust and rapid detection method for prenatal diagnosis. Expert Rev Mol Diagn. 2014;14(3):273–280.
Vialard F, Simoni G, Aboura A, et al. Prenatal BACs-on-BeadsTM: a new technology for rapid detection of aneuploidies and microdeletions in prenatal diagnosis. Prenat Diagn. 2011;31(5):500–508.
Choy KW, Kwok YK, Cheng YK, et al. Diagnostic accuracy of the BACs-on-BeadsTM assay versus karyotyping for prenatal detection of chromosomal abnormalities: a retrospective consecutive case series. BJOG. 2014;121(10):1245–1252.
Vialard F, Simoni G, Gomes DM, et al. Prenatal BACs-on-BeadsTM: the prospective experience of five prenatal diagnosis laboratories. Prenat Diagn. 2012;32(4):329–335.
Grati FR, Molina Gomes D, Ferreira JC, et al. Prevalence of recurrent pathogenic microdeletions and microduplications in over 9500 pregnancies. Prenat Diagn. 2015;35(8):801–809.
Cheng YK, Wong C, Wong HK, et al. The detection of mosaicism by prenatal BoBsTM. Prenat Diagn. 2013;33(1):42–49.
García-Herrero S, Campos-Galindo I, Martínez-Conejero JA, et al. BACs-on-beads technology: a reliable test for rapid detection of aneuploidies and microdeletions in prenatal diagnosis. Biomed Res Int. 2014;2014(13):590298.
Shaffer LG, Coppinger J, Morton SA, et al. The development of a rapid assay for prenatal testing of common aneuploidies and microdeletion syndromes. Prenat Diagn. 2011;31(8):778–787.
Ensenauer RE, Adeyinka A, Flynn HC, et al. Microduplication 22q11.2, an emerging syndrome: clinical, cytogenetic, and molecular analysis of thirteen patients. Am J Hum Genet. 2003;73(5):1027–1040.
Portnoï MF. Microduplication 22q11.2: a new chromosomal syndrome. Eur J Med Genet. 2009;52(2-3):88–93.
Weisfeld-Adams JD, Edelmann L, Gadi IK, Mehta L. Phenotypic heterogeneity in a family with a small atypical microduplication of chromosome 22q11.2 involving TBX1. Eur J Med Genet. 2012;55(12):732–736.
Dugoff L, Norton ME, Kuller JA. The use of chromosomal microarray for prenatal diagnosis. Am J Obstet Gynecol. 2016;215(4):B2–B9.
Xia Y, Yang Y, Huang S, Wu Y, Li P, Zhang J. Clinical application of chromosomal microarray analysis for the prenatal diagnosis of chromosomal abnormalities and copy number variations in fetuses with congenital heart disease. Prenat Diagn. 2018;38(6):406–413.
Fan Y, Wu Y, Wang L, et al. Chromosomal microarray analysis in developmental delay and intellectual disability with comorbid conditions. BMC Med Genomics. 2018;11(1):49.
Lee JS, Hwang H, Kim SY, et al. Chromosomal microarray with clinical diagnostic utility in children with developmental delay or intellectual disability. Ann Lab Med. 2018;38(5):473–480.
Wu Y, Wang Y, Tao J, et al. The clinical use of chromosomal microarray analysis in detection of fetal chromosomal rearrangements: a study from China Mainland. Eur J Obstet Gynecol Reprod Biol. 2017;212:44–50.
Malan V, Lapierre JM, Egloff M, et al. A French approach to test fetuses with ultrasound abnormalities using a customized microarray as first-tier genetic test. Cytogenet Genome Res. 2015;147(2-3):103–110.
Wapner RJ, Martin CL, Levy B, et al. Chromosomal microarray versus karyotyping for prenatal diagnosis. N Engl J Med. 2012;367(23):2175–2184.
Evans MI, Evans SM, Bennett TA, Wapner RJ. The price of abandoning diagnostic testing for cell-free fetal DNA screening. Prenat Diagn. 2018;38(4):243–245.
Hui L, Norton M. What is the real “price” of more prenatal screening and fewer diagnostic procedures? Costs and trade-offs in the genomic era. Prenat Diagn. 2018;38(4):246–249.
Harper LM, Sutton AL, Longman RE, Odibo AO. An economic analysis of prenatal cytogenetic technologies for sonographically detected fetal anomalies. Am J Med Genet A. 2014;164A(5):1192–1197.